Mechanistic examination of protein release from polymer nanofibers.
Therapeutic proteins have emerged as a significant class of pharmaceutical agents over the past several decades. The potency, rapid elimination, and systemic side effects have prompted the need of spatiotemporally controlled release for proteins maybe more than any other active therapeutic molecules. This work examines the release of two model protein compounds, bovine serum albumin (BSA) and an anti-integrin antibody (AI), from electrospun polycaprolactone (PCL) nanofiber mats. The anti-integrin antibody was chosen as a model of antibody therapy; in particular, anti-integrin antibodies are a promising class of therapeutic molecules for cancer and angiogenic diseases. The release kinetics were studied experimentally and interpreted in the framework of a recently published theory of desorption-limited drug release from nondegrading--or very slowly degrading--fibers. The results are consistent with a protein release mechanism dominated by desorption from the polymer surface, while the polycaprolactone nanofibers are not degrading at an appreciable rate.
Gandhi
M
M
Department of Biopharmaceutical Sciences, University of Illinois, Chicago, Illinois 60612-7231, USA.
Srikar
R
R
Yarin
A L
AL
Megaridis
C M
CM
Gemeinhart
R A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism*; D002417:Cattle; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000276:immunology*; D049329:Nanostructures; D011091:Polyesters / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism*; D014471:Umbilical Veins / Q000166:cytology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D039302:Integrin alphaVbeta3; D011091:Polyesters; D011108:Polymers; C016240:polycaprolactone; D012710:Serum Albumin, Bovine